23 Jul, 2026
According to Straits Research the global flow cytometry in oncology market was valued at $2613.36 million in 2025 and is anticipated to grow from $2926.97 million in 2026 to $7247.06 million by 2034, registering a CAGR of 12% during the forecast period 2026–2034.Flow cytometry is applied in oncology for the quantitative detection and evaluation of the physical and chemical properties of malignant cells within a particular sample. Flow cytometry is commonly used to identify malignant cell types in hematological malignancies by identifying cell surface antigens, which provide crucial information regarding the maturation stage and phenotypic heterogeneity. Although flow cytometry has been a cornerstone in detecting and screening hematological malignancies, its clinical use in solid tumors needs to be better understood.
Numerous public and commercial organizations actively fund R&D for the progress of hematologic malignancy testing. For example, in October 2019, the Leukemia and Lymphoma Society (LLS) granted USD 13.8 million for pediatric blood cancer research. Several universities, including the Johns Hopkins University School of Medicine, the New York University School of Medicine, the University of Michigan, and the University of Florida, received financing from LLS (U.S.). The given funds will assist twenty research projects on juvenile blood malignancies. In addition, the Leukemia Research Foundation contributed USD 1.2 million to research in July 2019. Therefore, research in the field of hematologic malignancies will likely rise due to technological advances to enable cancer screening, such as the development of next-generation flow cytometry-based cancer diagnostic tools. Increasing research funding for various types of blood malignancies by multiple organizations is expected to have a favorable impact on the growth of the worldwide flow cytometry in the oncology market throughout the forecast period.
One of the significant factors influencing the expansion of global flow cytometry in the oncology market is the increasing need for cost-effective and efficient diagnostic techniques, such as flow cytometry, as well as its subsequent technological advancements. The development of a multiparametric method for the diagnosis of hematological malignancies emphasizes the immunophenotypic, morphologic, and genotypic aspects of each disease subtype effectively. Multiparametric flow cytometry is a differential diagnostic technique that provides comprehensive prognostic information. In addition, the recent improvements in the treatment-based outcomes of hematological malignancies have led to the routine clinical deployment of minimal residual disease (MRD) testing. The recent invention of a multicolor flow cytometry panel enables the monitoring and detecting of residual cells in hematologic malignancies with a sensitivity of 10-4 cells, improving therapeutic results regarding relapse evaluation and therapy protocol selection.
North America is the most significant global flow cytometry in oncology market shareholder and is estimated to exhibit a CAGR of 10.9% over the forecast period. Several legacy companies in the flow cytometry industry in North America are now modernizing their portfolios to offer advanced cancer detection and screening solutions. In addition, the rising prevalence and incidence of numerous hematological malignancies have increased the demand for enhanced flow cytometry-based cancer testing solutions to evaluate the cellular features of malignant neoplasms. Further, the increasing adoption of multiparametric and next-generation flow cytometry technologies for routine cancer testing in the U.S. is a significant factor driving market expansion.
Europe is predicted to grow at a CAGR of 12.12% over the forecast period. Numerous European nations, including Germany, the United Kingdom, France, Italy, Spain, and the Netherlands, consistently work to improve research initiatives in flow cytometry in the cancer industry throughout Europe. Due to substantial funding infusions, the region has long been at the forefront of research to develop cancer diagnosis and treatment globally. At the end of 2021, Europe launched a new initiative titled "Cancer Diagnosis and Treatment for All," enabling physicians and researchers to enhance access to novel cancer detection and treatment solutions. In addition, the European Initiative to Understand Cancer, which aims to identify persons at high risk of developing common malignancies, was launched in 2021. The introduction of these projects is expected to ensure scientific excellence in the field of oncology, which is often motivated by a desire to comprehend the role of cellular phenotypic abnormalities in Cancer, which is anticipated to provide lucrative chances in the coming years.
sales@straitsresearch.com